聯系電話
上海允麥生物科技有限公司
中級會員·7年
- 聯系人：
- 麥經理
- 電話：
- 86-021-34553900
- 手機：
- 15121004110
- 傳真：
- 86-021-34553900
- 地址：
- 上海市青浦區
- 個性化：
- www.shymbio.com
- 網址：
- www.shymbio.com
掃一掃訪問手機商鋪
Recombinant human VG5Q
AGGF 1; AGGF-1; Angiogenic factor VG5Q; Angiogenic factor with G patch and FHA domains 1; FLJ10283; G patch domain containing protein 7; GPATC 7; GPATC7; GPATCH 7; GPATCH7; HSU84971; HUS84971; hVG5Q; Vasculogenesis gene on 5q; Vasculogenesis gene on 5q protein; AGGF1_HUMAN.
濃度：1mg/ ml
來源：Recombinant Human
純度：≥95% SDS-PAGE
表達系統：Escherichia coli
標簽：His tag
蛋白長度：Full length protein
內毒素水平：<1.000 Eu/µg
純化方法：HPLC
應用：SDS-PAGE，Western blot，ELISA
Biological activity,immunology research
保存：-20℃
保質期：1年
Angiogenic factors are critical to the initiation of angiogenesis and maintenance of the vascular network. VG5Q protein acts as a potent angiogenic factor in promoting angiogenesis, and suppression of VG5Q expression inhibits vessel formation. VG5Q shows strong expression in blood vessels and is secreted as vessel formation is initiated. VG5Q can bind to endothelial cells and promote cell proliferation, suggesting that it may act in an autocrine fashion. It also interacts with another secreted angiogenic factor, TWEAK (also known as TNFSF12). VG5Q is defective in patients with the vascular disease Klippel-Trenaunay syndrome (KTS).
Recombinant human VG5Q
AGGF 1; AGGF-1; Angiogenic factor VG5Q; Angiogenic factor with G patch and FHA domains 1; FLJ10283; G patch domain containing protein 7; GPATC 7; GPATC7; GPATCH 7; GPATCH7; HSU84971; HUS84971; hVG5Q; Vasculogenesis gene on 5q; Vasculogenesis gene on 5q protein; AGGF1_HUMAN.
濃度：1mg/ ml
來源：Recombinant Human
純度：≥95% SDS-PAGE
表達系統：Escherichia coli
標簽：His tag
蛋白長度：Full length protein
內毒素水平：<1.000 Eu/µg
純化方法：HPLC
應用：SDS-PAGE，Western blot，ELISA
Biological activity,immunology research
保存：-20℃
保質期：1年
Angiogenic factors are critical to the initiation of angiogenesis and maintenance of the vascular network. VG5Q protein acts as a potent angiogenic factor in promoting angiogenesis, and suppression of VG5Q expression inhibits vessel formation. VG5Q shows strong expression in blood vessels and is secreted as vessel formation is initiated. VG5Q can bind to endothelial cells and promote cell proliferation, suggesting that it may act in an autocrine fashion. It also interacts with another secreted angiogenic factor, TWEAK (also known as TNFSF12). VG5Q is defective in patients with the vascular disease Klippel-Trenaunay syndrome (KTS).
